CD274 and neoplasm: Current biomarkers, such as PD-L1 expression and tumor mutational burden, provide some predictive value but are not universally applicable across all tumor types or patients.528 The complexity of tumors and the dynamic nature of the immune response make it challenging to find biomarkers that consistently predict who will benefit from immunotherapy.